The Plague of Lonely Leftist Cat Women
The Cost of Free Money
'60 Minutes' Takes Extra Time to Clean Up Kamala's Mess, and the Lamest...
When Kamala Harris' Promises Come to Nothing
Kamala's Parade of (Mostly) Pablum Interviews
Black Clergy Speak Out for Israel
One Year Later
Free Speech in the Crosshairs
Government Employees Exceed Population of Florida
Trump’s Bounce from Butler and Elon
Do Rocks on Mars Have Rights?
Highway to Hell
Social Media Must Become a Bastion for Free Speech
Is This Really How POLITICO Covered Hurricane Milton's Threat to Florida?
Kamala Harris' '60 Minutes' Interview Was Worse Than CBS News Wants to Let...
Tipsheet

Beckman Finally Receives FDA Clearance on Troponin

Danaher Corp. (DHR, $69.77) announced Thursday afternoon that its subsidiary, Beckman Coulter, has received FDA clearance of its new Access AccuTnI+3 troponin I assay for use on the UniCel DxI series of immunoassay systems.Beckman, with expertise in cardiac disease management, was acquired by Danaher in 2011, after problems with its cardiac test,Troponin, led to a recall and financial problems.The FDA approval is a minor positive for Danaher stock, and closes the door on a difficult period in Beckman’s history.

Advertisement

Danaher is a science and technology company that manufactures diversified products, with locations in more than 50 countries. Its revenues are expected to grow 8 and 9% in 2013 and ’14 through internal growth via new and enhanced products, and through acquisitions.

Earnings are expected to grow 7-12% per year over the next three years, from expense control, and margin enhancement via the consolidation of recent acquisitions. The PE is 20.5, in a steady five-year range of 12-23.

The company has a solid balance sheet and strong cash flow, with intentions to repurchase 10 million shares, invest in R&D, and continue acquiring companies.

Danaher’s stock price is on a steady, long-term uptrend and appears immediately capable of continuing to climb.The valuation seems pricey, and I would instead concentrate new purchases on stocks with faster earnings growth.If I were enamored with Danaher and intent on owning shares, I’d wait, and hope for a pullback below $66.

Advertisement

Stock chart:

DHR Chart

DHR data by YCharts

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement